Primary Care Provider Evaluation of Cancer Survivorship Care Plans Developed for Patients in their Practice

Kim L. Dittus¹, Brian L. Sprague², Claire M. Pace³, Dorothy A. Dulko⁴, Lori A. Pollack⁵, Nikki A. Hawkins⁶, and Berta M. Geller⁶
¹Hematology/Oncology Division, University of Vermont, College of Medicine, Burlington, USA
²Department of Surgery and Office of Health Promotion Research, University of Vermont, Burlington, USA
³Department of Radiation Oncology, Dartmouth Medical School, Lebanon, USA
⁴Memorial Sloan Kettering Cancer Center, New York, New York, USA
⁵Centers for Disease Control and Prevention, Division of Cancer Prevention and Control, Atlanta, USA
⁶Family Medicine and Radiology Departments, University of Vermont, College of Medicine, Burlington, USA

Abstract

Objective—Survivorship care plans (SCP), which describe a cancer survivor’s diagnosis, treatment and follow-up, are recommended. The study objective was to evaluate primary care providers’ (PCP) responses to SCPs developed for breast and colorectal cancer survivors in their practice and to determine whether PCP response to the SCPs varied according to characteristics of the practitioner and their practice.

Method—SCPs were created using the Journey Forward® Care Plan for breast and colorectal cancer patients in rural and urban settings. The SCP and a survey were sent to PCPs.

Participants—Primary care physicians.

Main Measures—Attitudes regarding survivorship care plans.

Results—Thirty-nine (70.9% response rate) surveys were completed. Most felt the SCP was useful (90%), that it enhanced understanding (75%) and that detail was sufficient (>80%). However, 15% disagreed that the care plan helped them understand their role, a perception especially prevalent among PCPs in the rural setting. Among PCPs with ≤18 years in practice, 95% agreed that the SCP would improve communication with patients, contrasted with 60% of those with >21 years in practice. The most common barrier to providing follow-up care was limited access to survivors.

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

*Corresponding author: Kim Dittus, University of Vermont, Given E-214, 89 Beaumont Ave, Burlington Vermont 05405, USA, Tel: 802-656-5487; Fax: 802-656-5493; kim.dittus@vtmednet.org.
Conclusions—While SCPs appear to improve PCPs understanding of a cancer diagnosis and treatment, clear delineation of each provider’s role in follow-up care is needed. Additional detail on which tests are needed and education on late and long term effects of cancer may improve coordination of care.

Keywords
Cancer survivor; Health communication; Care transitions

Introduction
Improvements in cancer screening and therapy have resulted in a growing number of cancer survivors. The transition between initial therapy and surveillance has unique challenges [1]. Oncology visits often continue but focus on cancer issues and do not include screening for other malignancies or general health monitoring. Previous research suggests that when care is shared between specialists and primary care providers (PCPs), survivors receive better health care [2–4]. Yet, the role of the PCP in survivorship care is often unclear and communication is inadequate between the oncologist, PCP and patient [5–7].

The 2005 Institute of Medicine report on cancer survivorship, From Cancer Patient to Cancer Survivor: Lost in Transition called for the development of cancer survivor documents for survivors and their PCPs [8]. In 2015 the American College of Surgeons Commission on Cancer will require a survivorship care plan (SCP) for cancer survivors [9]. A SCP has the potential to facilitate communication about the oncology experience. Ideally, it provides a clear outline of the diagnosis, treatments received, plan for monitoring and clarifies the roles of the medical providers involved in the survivor’s care.

PCPs clearly favor the receipt of a summary of cancer diagnosis and care [6,10] and their perceptions of SCPs have been positive [11]. However, there is limited research evaluating how PCPs perceive SCPs developed for their own patients. It is also unknown whether the needs and preferences of PCPs in different practice settings differ regarding follow up care of cancer survivors. We evaluated PCPs’ understanding of and satisfaction with SCPs prepared for breast and colorectal cancer survivors in their practice. Additionally we examined whether PCP response to the SCPs varied according to characteristics of the practitioner and their practice.

Methods
SCPswere developed for breast and colorectal cancer patients and mailed to their PCPs at an urban and rural cancer center. In 2010, the urban area had a census of greater than 150,000, while the rural area had a population of approximately 31,000. All stage 0–3 breast cancer and stage 2–4 colorectal cancer patients who received intent to cure oncologic interventions between January 2011 and July 2011 were eligible to receive a SCP. A total of 89 patients were invited to participate in the study and 78 agreed (88%), including 61 with breast cancer and 17 with colorectal cancer.
Document development and delivery

Journey Forward® software was used to create the SCP [12]. The content followed the IOM report recommendations to include a summary of cancer type, treatment and treatment related complications, recommendations for follow up and the type of provider to see for follow up care, information on secondary cancer prevention and health promotion, and local resources [8]. Diagnosis and treatment information was obtained from medical records. The document was provided to both the cancer survivor and their PCP.

Prior to study initiation two survivor focus groups (one for breast cancer participants, one for colorectal cancer participants) were conducted to review sample Journey Forward care plans and the explanatory material for SCPs. Focus group participants were recruited from the Vermont Cancer Survivor Registry [13]. All focus groups lasted approximately 90 minutes. Additionally, three PCPs reviewed SCP templates and the survey for ease of use and completeness.

The SCP documents were prepared at each cancer center by an advanced practice provider (Nurse Practitioner or Physician Assistant) who had training in cancer survivor issues. The same practitioner also presented and discussed the SCP with cancer survivors. If inconsistencies in the SCP were identified by the patient at the time of the visit the information in question was re-examined and corrected in the SCP.

Survivor and PCP recruitment

At the urban center all eligible patients presenting for a first or second post therapy visit were informed that their next clinic visit would be an hour long survivorship visit which would include usual review of side effects and monitoring and a discussion of the SCP. At the visit they were informed of the opportunity to participate in a study to evaluate the SCP. If they agreed to participate in the longer visit and receive the document, an informed consent was signed. At the rural center patients were approached at the end of initial oncologic therapy and asked if they would like to receive a separate survivor visit and SCP. If the patient signed consent they were scheduled for a 1 hour long survivor visit 1–3 months later (i.e., same time frame as for the urban clinic visit). Several days prior to the visit, patients at both sites received a reminder call that the appointment was approaching.

PCP Survey development and administration

A survey was developed by study investigators to evaluate PCPs perceptions of the SCPs they received for patients in their care. The survey included the following topics: understanding of the patient’s treatment and follow up; adequacy of content detail; communication; and barriers to caring for cancer survivors. The survey used a 5-point Likert scale with five responses ranging from “Strongly Agree” to “Strongly Disagree”. Participants were asked to circle the number corresponding to their level of agreement with each statement. Demographic information about their practice was collected.

The SCP was mailed to the PCPs with a cover letter explaining the study, the survey and a self-addressed stamped return envelope. The return of the survey implied consent at the urban center. At the rural center PCP’s returning the survey also returned a signed IRB
approved consent. If a PCP received two SCPs he/she only received a survey with the first SCP. If the survey was not returned, two attempts were made to contact the PCP by mail. PCPs who did not return the survey within 4–8 weeks were contacted via email by an oncologist involved in the study at the urban center, while at the rural center an administrative secretary called the PCP.

**Statistical analysis**

Descriptive statistics were calculated to determine survey response frequencies and the distribution of demographic variables. Likert scale responses for strongly agree and agree as well as strongly disagree and disagree were collapsed in order to obtain categories with sufficient sample sizes for analysis. Descriptive statistics were used to assess differences between urban and rural PCPs responses and between those in practice less than or equal to and greater than the median of 18 years. Fisher’s exact test was used to identify statistically significant (p<0.05) differences according to these factors. All statistical analyses were conducted using SAS Statistical Software (Version 9; SAS Institute, Inc., Cary, North Carolina).

**Results**

Of the 55 surveys sent to PCPs, 39 were returned for a response rate of 70.9%. We received 22 surveys from PCP’s in the urban area and 17 from PCP’s in the rural area. Demographic characteristics of respondents are summarized in Table 1. The majority of respondents were female and family practice physicians. The demographic characteristics between rural and urban centers were similar other than a predominance of female providers in the rural area.

Nearly all PCP’s reported that the SCP was easy to understand (97%), incorporated appropriate topics (97%) and was useful (90%). However 16% disagreed that the length of the SCP (which was on average 5 pages) was "just right". Written comments concurred that several PCPs felt the SCP was too long.

**Understanding SCP information**

Greater than 75% of PCP’s felt the SCP contributed to their understanding of the cancer diagnosis, treating team, recommendations for follow up, and resources available for survivorship care, with no statistically significant differences between urban and rural sites (Table 2).

PCPs in practice >18 years were significantly less likely to endorse that the SCP contributed to their understanding of the cancer diagnosis (p-interaction=0.04) and were less likely to agree that they understood the follow-up for late or chronic problems resulting from cancer treatment (p-interaction=0.02). A proportion of respondents (15%) disagreed that the care plan helped them understand their role in facilitating survivorship care and 15% disagreed that they understood how responsibility would be shared with the oncologist. The PCPs from the rural site were less likely to agree that the SCP contributed to their understanding of their role (p-interaction=0.05).
Adequacy of content detail

The survey assessed whether the level of detail in the SCP was adequate to perform several tasks (Table 3). Greater than 80% of respondents agreed that the level of detail was sufficient and response was similar for years in practice. However, the rural PCP’s were less likely than the urban PCPs to agree that the SCPs provided sufficient detail about monitoring for late and long term effects and tests to obtain for monitoring. There was no significant difference in the perception of SCP content detail by years in practice.

Communication

Over 70% of PCP’s at each site agreed that SCPs would improve communication with medical providers and patients (Table 4).

Perceptions about improved communication with patients were similar among urban and rural PCPs, but differed according to years in practice. Among those with ≤18 years in practice, 95% of PCPs agreed that the SCP would improve communication with patients, whereas only 60% of PCPs with >18 years in practice agreed (p-interaction= 0.03). Despite general agreement that the SCP was useful, 13% of all respondents either did not care if they received SCP documents or did not want to receive them. There was no statistically significant difference in desire to receive SCPs by site or years in practice.

Barriers to providing survivorship care identified by PCP’s are included in Table 5. The most common barrier to providing follow-up care was “limited access to survivors since they stay with their oncologist” with 64% considering this a significant or moderate barrier. PCP’s practicing for less than 18 years were significantly more likely to feel that insufficient knowledge of cancer survivorship issues was a barrier to survivor care (79% vs. 36.8%). Overall, only 18% felt that poor reimbursement was a barrier (Table 5).

Discussion

In general, PCP’s felt that SCPs developed for their patients contributed to their understanding of the cancer diagnosis and treatment and would improve communication with cancer treatment providers and survivors. However, we discovered differences between urban and rural PCPs and those in practice less than 18 years compared with those in practice longer. We also found that PCPs encounter substantial barriers in providing survivorship care.

Our survey results are consistent with a recent study based on semi-structured interviews of primary care providers receiving SCPs for their patients who felt SCPs increased their knowledge about their patient’s cancer history and recommendations for surveillance [11]. There were two notable exceptions regarding the agreement between the two studies: 1) the role of PCP and oncologist in survivorship care and; 2) division of responsibility for monitoring for recurrence and new primary cancers.

Despite receiving a SCP for a specific patient, many urban and rural PCPs remained unclear about their role in survivorship care and how primary care and oncology might share responsibility. The rural PCPs were significantly less likely to understand their role in
follow up care and continuing education efforts should target them. There is not a defined
time to transfer the care of a cancer survivor from oncology to primary care. Commonly
patients continue to see both a PCP and an oncologist for an extended period making it
difficult to clearly delineate who is responsible for follow up care. As a result, many aspects of
survivorship follow up may remain ambiguous. Additionally, a majority of PCPs feel that
primary care guidelines for adult cancer survivors are not well defined [14].

Significant differences have been reported between oncologists and PCPs in the attitudes,
knowledge and practices for cancer survivor care [15]. PCPs express concern that they do
not know what surveillance tests are needed or the appropriate duration of surveillance
[5,11]. They are also more likely to endorse the use of non-recommended tests for follow up
than are oncologists [15]. The SCP should clearly specify which physician is responsible for
ordering which monitoring test. This will require clear guidelines from national professional
organizations which incorporate input from oncologists and PCPs and define follow up
monitoring and the role of the PCP in cancer survivor care. Oncology organizations should
be encouraged to establishing clear guidelines delineating responsibility of cancer survivor
care.

PCPs in practice a longer time expressed less understanding of the requirements for
monitoring for late or chronic problems that result from cancer therapy. As cancer therapy
has become more complex, primary care providers further from initial training may be
unfamiliar with newer interventions and less aware of the current consequences of cancer
therapy. Knowledge of the late and long term impact of cancer therapy is important for
PCPs as patients may see them first about these symptoms and late and lingering effects may
impact organ systems for which the patient is being monitored.

PCPs generally agreed that the detail in the SCP was adequate. However, PCP’s from the
rural area were significantly less likely to agree that the SCP provided sufficient content to
help them obtain tests for monitoring. Perhaps PCP’s in the urban area, who were often
associated with an academic center, receive more cancer related education or presumed they
had easier access to oncologists should questions arise. Additionally, actual monitoring
recommendations may be less clearly defined than PCP’s anticipate and recommendations
vary by cancer type which contributes to confusion about surveillance.

Insufficient knowledge of cancer survivor issues was a commonly identified barrier among
PCPs and may partially explain why they felt the SCP provided insufficient detail. PCP
uncertainty about late effects of cancer and follow up care recommendations has been
identified by others [15]. Given the uncertainty PCPs have about late effects and what tests
are needed for monitoring, continuing medical education should include more information
about cancer therapy, long term and late effects of therapy, and surveillance of recurrence
and new primary cancers.

Our findings have several limitations. The small sample size limits statistical power to detect
small differences in responses by PCP characteristics. The use of a quantitative survey is
also a limitation, as a qualitative approach may have provided a richer understanding of the
complexities faced by PCPs when using information contained in a SCPs in a busy practice.

*J Gen Pract (Los Angel)*. Author manuscript; available in PMC 2015 October 06.
While the response rate was high, non-respondents may have differed in their assessment of the SCPs. Despite including PCPs practicing in both urban and rural areas, the survey was administered in a geographically localized area which limits generalizability of the study results. Participating PCPs in the urban area may be more integrated with the academic cancer center where most of their patients would receive oncologic care. They may also have more education opportunities and greater access to oncologists thus alleviating concerns about monitoring.

SCP,
s have the potential to strengthen communication, facilitate care coordination, clarify roles, and lessen PCPs anxiety about providing adequate care, thus increasing the opportunity for more primary care of cancer survivors. PCPs in rural and urban areas appear to find SCPs developed for their patients understandable and the content sufficiently detailed for most topics. However, usefulness of SCPs can be enhanced. Given the time challenges PCPs face SCP should as short and precise as possible. Clear delineation of roles between PCPs and oncologists and specific information within the SCP regarding late and long term effects and monitoring tests are needed. Oncology organizations should be encouraged to develop well-defined follow up recommendations. Ideally a SCP could be updated as new information regarding impacts of cancer treatment and follow up recommendations evolve.

A disease and care management model that empowers patients, which improves health care team collaboration and patient outcomes has been found to be beneficial for patient with chronic disease [16] and would likely enhance cancer survivor care. This approach would be a particular advantage in rural settings by helping facilitate appropriate testing and communication with specialists. At a minimum, continuing education regarding cancer survivor issues will help relieve the dissonance PCPs may feel about assuming a larger role in cancer survivor care and their perception of insufficient knowledge of survivor issues and follow up.

Acknowledgements

The authors would like to thank Jennifer Hausman and others at Journey Forward® for their assistance in using the Survivorship Care Plan Builder, and Kathleen Howe, Penelope Gibson, Janet Ely, Elizabeth McGrath, Amy Nolan, Annie Dorwalda, Greg Dana, Dawn Pelkey, and Rachael Chicoine for their assistance in the creation of the survivorship care plans, subject recruitment, data collection, and study support.

Funding

This work was supported by the Centers for Disease Control and Prevention (5U48DP001935-02; SIP 10-029). The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

References

1. Rowland JH. What are cancer survivors telling us? Cancer J. 2008;14:361–368. [PubMed: 19060600]
2. Earle CC, Burstein HJ, Winer EP, Weeks JC. Quality of non-breast cancer health maintenance among elderly breast cancer survivors. J Clin Oncol. 2003;21:1447–1451. [PubMed: 12697865]
3. Earle CC, Neville BA. Under use of necessary care among cancer survivors. Cancer. 2004;101:1712–1719. [PubMed: 15386307]
4. Keating NL, Landrum MB, Guadagnoli E, Winer EP, Ayanian JZ. Factors related to underuse of surveillance mammography among breast cancer survivors. J Clin Oncol. 2006;24:85–94. [PubMed: 16382117]
5. Nissen MJ, Beran MS, Lee MW, Mehta SR, Pine DA, et al. Views of primary care providers on follow-up care of cancer patients. Fam Med. 2007; 39:477–482. [PubMed: 17602321]

6. Kantisiper M, McDonald EL, Geller G, Shockney L, Snyder C, et al. Transitioning to breast cancer survivorship: perspectives of patients, cancer specialists, and primary care providers. J Gen Intern Med. 2009; 24(Suppl 2):S459–S466. [PubMed: 19838851]

7. Cheung WY, Neville BA, Cameron DB, Cook EF, Earle CC. Comparisons of patient and physician expectations for cancer survivorship care. J Clin Oncol. 2009; 27:2489–2495. [PubMed: 19332716]

8. Grant M, Economou D, Ferrell B, Uman G. Educating health care professionals to provide institutional changes in cancer survivorship care. J Cancer Educ. 2012; 27:226–232. [PubMed: 22271583]

9. Commission on Cancer. Cancer Program Standards 2012: Ensuring Patient-Centered Care. Chicago, IL: American College of Surgeons; 2012.

10. Salz T, Oeffinger KC, McCabe MS, Layne TM, Bach PB. Survivorship care plans in research and practice. CA Cancer J Clin. 2012

11. Shalom MM, Hahn EE, Casillas J, Ganz PA. Do survivorship care plans make a difference? A primary care provider perspective. J Oncol Pract. 2011; 7:314–318. [PubMed: 22211129]

12. Hausman J, Ganz PA, Sellers TP, Rosenquist J. Journey forward: the new face of cancer survivorship care. Am J Manag Care. 2011; 17:e187–e193. [PubMed: 21711070]

13. Geller BM, Mace J, Vacek P, Johnson A, Lamer C, et al. Are cancer survivors willing to participate in research? J Community Health. 2011; 36:772–778. [PubMed: 21311959]

14. Bober SL, Recklitis CJ, Campbell EG, Park ER, Kutner JS, et al. Caring for cancer survivors: a survey of primary care physicians. Cancer. 2009; 115:4409–4418. [PubMed: 19731354]

15. Potosky AL, Han PK, Rowland J, Klabunde CN, Smith T, et al. Differences between primary care physicians’ and oncologists’ knowledge, attitudes and practices regarding the care of cancer survivors. J Gen Intern Med. 2011; 26:1403–1410. [PubMed: 21785923]

16. Ciccone MM, Aquilino A, Cortese F, Scicchitano P, Sassara M, et al. Feasibility and effectiveness of a disease and care management model in the primary health care system for patients with heart failure and diabetes (Project Leonardo). Vasc Health Risk Manag. 2010; 6:297–305. [PubMed: 20479952]
Table 1
Demographic data on responding primary care providers by practice setting.

| Characteristic     | Urban (%) n=22 | Rural (%) n=17 |
|--------------------|----------------|----------------|
| Specialty          |                |                |
| Family Medicine    | 15 (68.2%)     | 13 (76.5%)     |
| Internal Medicine  | 6 (27.3%)      | 2 (17.7%)      |
| OB/Gyn             | 1 (4.6%)       | 0              |
| NP/PA              | 0              | 1 (5.9%)       |
| Gender             |                |                |
| Male               | 11 (50%)       | 5 (29.4%)      |
| Female             | 11 (50%)       | 12 (70.6%)     |
| Median Years of Practice | 17 (range 1–36) | 20 (range 10–38) |
### Table 2

Primary care providers’ understanding of components of cancer survivors’ follow up care.

| Component                                                                 | Total (%) | Urban (%) | Rural (%) | P value | ≤18 yrs (%) | >18 yrs (%) | P value |
|----------------------------------------------------------------------------|-----------|-----------|-----------|---------|-------------|-------------|---------|
| **Your patient’s cancer diagnosis**                                        |           |           |           |         |             |             |         |
| Agree                                                                      | 29 (87.9)| 18 (81.8)| 11 (100) | 0.38    | 17 (100)   | 12 (75.0)   | 0.04*   |
| Neutral                                                                    | 2 (6.1)  | 2 (9.1)  | 0         | 0       | 2 (12.5)   |             |         |
| Disagree                                                                   | 2 (6.1)  | 2 (9.1)  | 0         | 0       | 2 (12.5)   |             |         |
| **The team who treated your patient for cancer**                           |           |           |           |         |             |             |         |
| Agree                                                                      | 35 (89.7)| 20 (91.0)| 15 (88.2)| 0.76    | 19 (100)   | 16 (80.0)   | 0.16    |
| Neutral                                                                    | 3 (7.7)  | 1 (4.5)  | 2 (11.8) | 0       | 3 (15.0)   |             |         |
| Disagree                                                                   | 1 (2.6)  | 1 (4.5)  | 0         | 0       | 1 (5.0)    |             |         |
| **The need for routine cancer screening**                                 |           |           |           |         |             |             |         |
| Agree                                                                      | 30 (76.9)| 17 (77.3)| 13 (76.5)| 0.50    | 17 (89.5)  | 13 (65.0)   | 0.15    |
| Neutral                                                                    | 7 (17.9) | 3 (13.6) | 4 (23.5) | 0       | 3 (15.0)   |             |         |
| Disagree                                                                   | 2 (5.1)  | 2 (9.1)  | 0         | 0       | 2 (10.0)   |             |         |
| **The need for follow-up to assess for late and/or chronic problems resulting from cancer treatment** |           |           |           |         |             |             |         |
| Agree                                                                      | 33 (84.6)| 19 (86.4)| 14 (82.5)| 0.82    | 19 (100)   | 14 (70.0)   | 0.02*   |
| Neutral                                                                    | 3 (7.7)  | 1 (4.5)  | 2 (11.8) | 0       | 3 (15.0)   |             |         |
| Disagree                                                                   | 3 (7.7)  | 2 (9.1)  | 1 (5.9)  | 0       | 3 (15.0)   |             |         |
| **Which follow-up tests will be needed**                                   |           |           |           |         |             |             |         |
| Agree                                                                      | 33 (84.6)| 20 (91.0)| 13 (76.5)| 0.43    | 18 (94.7)  | 15 (75.0)   | 0.21    |
| Neutral                                                                    | 4 (10.3) | 1 (4.5)  | 3 (17.6) | 1 (5.3) | 3 (15.0)   |             |         |
| Disagree                                                                   | 2 (5.1)  | 1 (4.5)  | 1 (5.9)  | 0       | 2 (10.0)   |             |         |
| **How often follow-up tests should be performed**                         |           |           |           |         |             |             |         |
| Agree                                                                      | 35 (89.7)| 20 (91.0)| 15 (88.2)| 0.76    | 18 (94.7)  | 17 (85.0)   | 0.99    |
| Neutral                                                                    | 3 (7.7)  | 1 (4.5)  | 2 (11.8) | 1 (5.3) | 2 (10.0)   |             |         |
| Disagree                                                                   | 1 (2.6)  | 1 (4.5)  | 0         | 0       | 1 (5.0)    |             |         |
| **The importance of resuming/initiating age appropriate health maintenance practices** |           |           |           |         |             |             |         |
| Agree                                                                      | 31 (79.5)| 18 (81.8)| 13 (76.5)| 0.82    | 18 (94.7)  | 13 (65.0)   | 0.06    |
| Did the information in the SCP contribute to your understanding regarding: | Total (%) n=39 | Urban (%) n=22 | Rural (%) n=17 | P value | ≤18 yrs (%) n=19 | >18 yrs (%) n=20 | P value |
|-------------------------------|----------------|--------------|---------------|---------|----------------|----------------|---------|
| Neutral                       |                |              |               |         |                |                 |         |
|                               | 7 (17.9)       | 3 (13.6)     | 4 (23.5)      |         | 1 (5.3)        | 6 (30.0)       |         |
| Disagree                      | 1 (2.6)        | 1 (4.6)      | 0             |         | 0              | 1 (5.0)        |         |
| **Your role in facilitating survivorship care** | | | | | | | |
| Agree                         | 24 (61.5)      | 15 (68.2)    | 9 (52.9)      | 0.05    | 12 (63.1)      | 12 (60.0)      | 0.99    |
| Neutral                       | 9 (23.1)       | 2 (9.1)      | 7 (41.2)      |         | 4 (21.1)       | 5 (25.0)       |         |
| Disagree                      | 6 (15.4)       | 5 (22.7)     | 1 (5.9)       |         | 3 (15.8)       | 3 (15.0)       |         |
| **How the PCP and oncology providers will share responsibility for survivorship care** | | | | | | | |
| Agree                         | 26 (66.7)      | 15 (68.2)    | 11 (64.7)     | 0.79    | 12 (63.1)      | 14 (70.0)      | 0.72    |
| Neutral                       | 7 (17.9)       | 3 (13.6)     | 4 (23.5)      |         | 3 (15.8)       | 4 (20.0)       |         |
| Disagree                      | 6 (15.4)       | 4 (18.2)     | 2 (11.8)      |         | 4 (21.1)       | 2 (10.0)       |         |
| **The resources available to cancer survivors/families** | | | | | | | |
| Agree                         | 30 (78.9)      | 18 (81.8)    | 12 (75.0)     | 0.70    | 15 (78.9)      | 15 (78.9)      | 0.99    |
| Neutral                       | 8 (21.1)       | 4 (18.2)     | 4 (25.0)      |         | 4 (21.1)       | 4 (21.1)       |         |
| Disagree                      | 0              | 0            | 0             |         | 0              | 0              |         |

*Significance between PCP’s from urban and rural practices (p<0.05)
†Significance between PCP’s based on years in practice (p<0.05)
Table 3

Primary care providers assessment of the adequacy of detail in survivorship care plans.

|                      | Total (%) | Urban (%) | Rural (%) | P value | ≤18 yrs (%) | >18 yrs (%) | P Value |
|----------------------|-----------|-----------|-----------|---------|-------------|-------------|---------|
|                      | n=39      | n=22      | n=17      |         | n=19        | n=20        |         |
| Cancer treatment care team |          |           |           |         |             |             |         |
| Agree                | 37 (94.9) | 20 (91.0) | 17 (100)  | 0.99    | 18 (94.7)   | 19 (95.0)   | 0.99    |
| Neutral              | 1 (2.6)   | 1 (4.5)   | 0         |         | 0           | 1 (5.0)     |         |
| Disagree             | 1 (2.6)   | 1 (4.5)   | 0         |         | 1 (5.3)     | 0           |         |
| Information about patient risk factors |          |           |           |         |             |             |         |
| Agree                | 33 (84.6) | 19 (86.4) | 14 (82.4) | 0.80    | 17 (89.5)   | 16 (80.0)   | 0.99    |
| Neutral              | 5 (12.8)  | 2 (9.1)   | 3 (17.6)  |         | 2 (10.5)    | 3 (15.0)    |         |
| Disagree             | 1 (2.6)   | 1 (4.5)   | 0         |         | 0           | 1 (5.0)     |         |
| Cancer specific diagnosis |        |           |           |         |             |             |         |
| Agree                | 36 (92.3) | 22 (100)  | 14 (82.4) | 0.07    | 19 (100)    | 17 (85.0)   | 0.23    |
| Neutral              | 3 (7.7)   | 0         | 3 (17.7)  |         | 0           | 3 (15.0)    |         |
| Disagree             | 0         | 0         | 0         |         | 0           | 0           |         |
| Treatment plan and summary |        |           |           |         |             |             |         |
| Agree                | 37 (94.9) | 21 (95.5) | 16 (94.1) | 0.69    | 18 (94.7)   | 19 (95.0)   | 0.99    |
| Neutral              | 1 (2.6)   | 0         | 1 (5.9)   |         | 1 (5.3)     | 0           |         |
| Disagree             | 1 (2.6)   | 1 (4.5)   | 0         |         | 0           | 1 (5.0)     |         |
| Follow-up care       |           |           |           |         |             |             |         |
| Agree                | 36 (94.7) | 20 (91.0) | 16 (100)  | 0.50    | 17 (94.4)   | 19 (95.0)   | 0.99    |
| Neutral              | 0         | 0         | 0         |         | 0           | 5 (5.6)     | 0       |
| Disagree             | 2 (5.3)   | 2 (9.0)   | 0         |         | 1           | 1 (5.0)     |         |
| Monitoring for late and long term effects |        |           |           |         |             |             |         |
| Agree                | 35 (89.7) | 22 (100)  | 13 (76.5) | 0.03*   | 18 (94.7)   | 17 (85.0)   | 0.61    |
| Neutral              | 4 (10.3)  | 0         | 4 (23.5)  |         | 1 (5.3)     | 3 (15.0)    |         |
| Disagree             | 0         | 0         | 0         |         | 0           | 0           |         |
| Tests to obtain for monitoring |        |           |           |         |             |             |         |
|                      | Total (%) | Urban (%) | Rural (%) | P value | ≤18 yrs (%) | >18 yrs (%) | P Value |
|----------------------|-----------|-----------|-----------|---------|-------------|-------------|---------|
|                      | n=39      | n=22      | n=17      |         | n=19        | n=20        |         |
| Agreement            |           |           |           |         |             |             |         |
| Agree                | 26 (86.7) | 21 (95.5) | 5 (62.5)  | 0.01 *  | 14 (93.3)   | 12 (60.0)   | 0.60    |
| Neutral              | 3 (10.0)  | 0         | 3 (37.5)  |         | 1 (6.7)     | 2 (13.3)    |         |
| Disagree             | 1 (3.3)   | 1 (4.5)   | 0         |         | 0           | 1 (6.7)     |         |
| Symptoms to watch for recurrence or second primary | | | | | | | |
| Agreement            |           |           |           |         |             |             |         |
| Agree                | 30 (93.8) | 19 (95.5) | 11 (91.7) | 0.99    | 15 (93.7)   | 15 (93.7)   | 0.99    |
| Neutral              | 0         | 0         | 0         |         | 0           | 0           |         |
| Disagree             | 2 (6.3)   | 1 (5.0)   | 1 (9.3)   |         | 1 (6.3)     | 1 (6.3)     |         |
| National and community resources | | | | | | | |
| Agreement            |           |           |           |         |             |             |         |
| Agree                | 33 (90.9) | 20 (91.0) | 13 (90.1) | 0.99    | 15 (83.3)   | 15 (100)    | 0.23    |
| Neutral              | 3 (9.1)   | 2 (9.0)   | 1 (9.9)   |         | 3 (17.7)    | 0           |         |
| Disagree             | 0         | 0         | 0         |         | 0           | 0           |         |

*Significance between PCP’s from urban and rural practices (p<0.05).*
Table 4

Primary care provider’s assessment of survivorship care plans impact on communication.

|                                      | Total (%) | Urban (%) | Rural (%) | P value | ≤18 yrs (%) | >18 yrs (%) | P value |
|--------------------------------------|-----------|-----------|-----------|---------|-------------|-------------|---------|
|                                      | N=39      | n=22      | n=17      |         | n=19        | n=20        |         |
| Do you think that the SCP will improve your communication with cancer treatment providers? |           |           |           |         |             |             |         |
| Agree                                 | 29 (74.4) | 15 (68.2) | 14 (82.3) | 0.65    | 14 (73.7)   | 15 (75.0)   | 0.99    |
| Neutral                               | 6 (15.4)  | 4 (18.2)  | 2 (11.8)  |         | 3 (15.8)    | 3 (15.0)    |         |
| Disagree                              | 4 (10.3)  | 3 (13.6)  | 1 (5.9)   |         | 2 (10.5)    | 2 (10.0)    |         |
| Do you think that the SCP will improve your communications with cancer survivors? |           |           |           |         |             |             |         |
| Agree                                 | 30 (76.9) | 18 (81.8) | 12 (70.6) | 0.63    | 18 (94.7)   | 12 (60.0)   | 0.03†   |
| Neutral                               | 6 (15.4)  | 3 (13.6)  | 3 (17.6)  |         | 1 (5.3)     | 5 (25.0)    |         |
| Disagree                              | 3 (7.7)   | 1 (4.6)   | 2 (11.8)  |         | 0           | 3 (15.0)    |         |
| Would you like to continue to receive SCPs for your patients? |           |           |           |         |             |             |         |
| Agree                                 | 33 (86.8) | 19 (90.5) | 14 (82.3) | 0.78    | 18 (94.7)   | 15 (79.0)   | 0.41    |
| Neutral                               | 3 (7.9)   | 1 (5.3)   | 2 (11.8)  |         | 1 (5.3)     | 2 (10.5)    |         |
| Disagree                              | 2 (5.3)   | 1 (5.3)   | 1 (5.9)   |         | 0           | 2 (10.5)    |         |

† Significance between PCP’s based on years in practice (p<0.05).
Table 5

Barriers primary care providers identify for providing follow up care for cancer survivors.

| Barrier that may interfere with PCPs ability to provide follow-up care for cancer survivors | Total (%) n=38 | Urban (%) n=22 | Rural (%) n=17 | P value | ≤18 yrs (%) n=19 | >18 yrs (%) n=20 | P value |
|------------------------------------------------------------------------------------------|----------------|---------------|----------------|---------|------------------|-----------------|---------|
| **Lack of time**                                                                          |                |               |                |         |                  |                 |         |
| Significant/Mod. Barrier                                                                 | 17 (44.7)      | 12 (54.5)     | 5 (31.3)       | 0.32    | 9 (47.4)         | 8 (42.2)        | 0.99    |
| Neutral                                                                                  | 7 (18.4)       | 4 (18.2)      | 3 (18.8)       |         |                  |                 |         |
| Hardy/Not a Barrier                                                                      | 14 (36.8)      | 6 (27.3)      | 8 (50.0)       |         |                  |                 |         |
| **Insufficient knowledge of cancer survivor issues**                                      |                |               |                |         |                  |                 |         |
| Significant/Mod. Barrier                                                                 | 22 (57.9)      | 13 (59.1)     | 9 (56.3)       | 0.36    | 15 (78.9)        | 7 (36.8)        | 0.02†   |
| Neutral                                                                                  | 8 (21.1)       | 6 (27.3)      | 2 (12.5)       |         |                  |                 |         |
| Hardy/Not a Barrier                                                                      | 8 (21.1)       | 3 (13.6)      | 5 (31.3)       |         |                  |                 |         |
| **Inadequate recommendations from oncology**                                             |                |               |                |         |                  |                 |         |
| Significant/Mod. Barrier                                                                 | 18 (48.7)      | 10 (47.6)     | 8 (50.0)       | 0.83    | 11 (61.1)        | 7 (36.8)        | 0.36    |
| Neutral                                                                                  | 9 (24.3)       | 6 (28.6)      | 3 (18.8)       |         |                  |                 |         |
| Hardy/Not a Barrier                                                                      | 10 (27.0)      | 5 (23.8)      | 5 (31.3)       |         |                  |                 |         |
| **Poor reimbursement for services**                                                      |                |               |                |         |                  |                 |         |
| Significant/Mod. Barrier                                                                 | 7 (18.4)       | 6 (27.3)      | 1 (6.3)        | 0.27    | 4 (21.1)         | 3 (15.8)        | 0.27    |
| Neutral                                                                                  | 16 (42.1)      | 9 (40.9)      | 7 (43.8)       |         |                  |                 |         |
| Hardy/Not a Barrier                                                                      | 15 (39.5)      | 7 (31.8)      | 8 (50.0)       |         |                  |                 |         |
| **Limited access to cancer survivors since they stay with oncology practices**           |                |               |                |         |                  |                 |         |
| Significant/Mod. Barrier                                                                 | 25 (64.1)      | 12 (54.6)     | 13 (76.5)      | 0.36    | 13 (68.4)        | 12 (60.0)       | 0.46    |
| Neutral                                                                                  | 9 (23.1)       | 7 (31.8)      | 2 (11.8)       |         |                  |                 |         |
| Hardy/Not a Barrier                                                                      | 5 (12.8)       | 3 (13.6)      | 2 (11.8)       |         |                  |                 |         |
| **Survivor care guidelines have not been established**                                   |                |               |                |         |                  |                 |         |
| Significant/Mod. Barrier                                                                 | 16 (47.1)      | 9 (42.9)      | 7 (53.8)       | 0.87    | 9 (50.0)         | 7 (43.8)        | 0.89    |
| Neutral                                                                                  | 15 (44.1)      | 10 (47.6)     | 5 (38.5)       |         |                  |                 |         |
| Hardy/Not a Barrier                                                                      | 3 (8.8)        | 2 (9.5)       | 1 (7.7)        |         |                  |                 |         |

† Significance between PCP’s based on years in practice (p<0.05).